CStone’s CS2009 trispecific antibody reinforces three clinical validations at ESMO
With data from over 300 patients across multiple tumor types and Phase 3 trials coming soon, the evidence supports CS2009’s mechanism, safety and antitumor efficacy Key Takeaways: CS2009 delivered strong…
RELATED ARTICLES
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG - AI in China’s medical aesthetics sector: From non-core services to clinical device integration
- Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Akeso’s overseas drug promise fails to slow share decline
9926.HK
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK
